Ownership of Developed Technology. As between Allergan and ASTI, Allergan shall own all Developed Technology, subject to the Technology License Agreement.
Ownership of Developed Technology. WATCHGUARD and SMART shall jointly own the Developed Technology, with each owning an undivided one-half interest, and except as otherwise provided herein each shall be free to commercially exploit the Developed Technology without any duty to account to the other for profits. Except as contemplated herein, neither party shall knowingly take any action to place the Developed Technology into the public domain. In the event that either party attempts to perfect its interest in the Developed Technology with any governmental agency any place in the world by obtaining patent or copyright protection or otherwise, such party shall specify on such application or document filed or sent to such governmental agency that the Developed Technology is jointly owned by WATCHGUARD and SMART and such party shall provide the other party hereto with an opportunity to review any such correspondence within a reasonable time prior to filing or sending such correspondence to such governmental agency. If either party receives any such correspondence regarding the Developed Technology, it shall promptly provide a copy of such correspondence to the other party hereto.
Ownership of Developed Technology. (a) All Technology Developed Solely by YETI shall be owned solely by YETI.
(b) All Technology Developed Jointly shall be owned solely by YETI.
(c) All Technology Developed Solely by Supplier shall be owned solely by Supplier, except that YETI shall solely own all Technology Developed Solely by Supplier that was or is:
(i) funded by YETI in whole or in part through separately-identified payments to Supplier for the design or development of any product, samples, tooling, molds or equipment,
(ii) developed for or with reference to a YETI development project that has been communicated to Supplier in writing, or
(iii) developed with reference to, or based wholly or partially on, YETI’s Confidential Information.
(d) Developed Technology identified in Sections 4.2(a), 4.2(b), and clauses (i) — (iii) of Section 4.2(c) shall be referred to as “YETI Developed Technology”, and Developed Technology identified in Section 4.2(c) (excluding clauses (i) — (iii) of said Section) shall be referred to as “Supplier Developed Technology”.
(e) Supplier shall irrevocably transfer and assign, and hereby does irrevocably transfer and assign, to YETI, in consideration of the payments made to Supplier pursuant to the Scopes of Work, all right, title and interest in and to all YETI Developed Technology, including any Intellectual Property in YETI Developed Technology. To the extent permitted by applicable law, Supplier hereby waives all moral rights or droits morale, for all time for all purposes, in the YETI Developed Technology.
Ownership of Developed Technology. As between the Parties, subject only to the licenses granted under ARTICLE 2, and Acologix’ ownership of Materials under Section 3.4:
(a) Acologix shall own all right, title and interest in and to any Intellectual Property that is made solely by Acologix (including Third Parties working on behalf of Acologix) or jointly by Acologix and Toray (including third parties working on behalf of Acologix and Toray) in the course of the R&D Program during the Term (“Acologix-Developed IP”); and
(b) Toray shall own all right, title and interest in and to any Intellectual Property that is made solely by Toray (including Third Parties working on behalf of Toray) in accordance with this Agreement during the Term (“Toray-Developed IP”).
Ownership of Developed Technology. Unless BioChem and CliniChem agree otherwise and except as set forth in Section 2.2 of the Technology License Agreement, all Developed Technology shall be owned by BioChem or a BioChem Affiliate (as determined by BioChem in its sole discretion) and exclusively licensed to CliniChem on a worldwide basis with the right to sublicense subject to the terms and conditions of the Technology License Agreement, subject to the Product Option and limited to the applicable Field of Use.
Ownership of Developed Technology. As between ALZA and Crescendo, ALZA shall own all Developed Technology (which shall be part of the ALZA Technology), subject to the Technology License Agreement.
Ownership of Developed Technology. Each Party shall own and retain the entire right, title and interest in and to all Developed Technology made solely by the employee(s) or agent(s) of such Party or any of its Affiliates, subject only to the rights expressly granted to the other Party under this Agreement. Following a determination of any rights of the Parties pursuant to the United States laws of inventorship, the Parties agree that Acerus shall be the sole and exclusive owner of any Developed Technology made jointly by employees or agents of both Parties and related to the NGDD Technology or the Product (a “Platform Improvement”) and Aytu shall be the sole and exclusive owner of any other Developed Technology made jointly by employees or agents of both Parties (a “Non-Platform Improvement”). Neither Party shall file for any patent that discloses or claims both a Platform Improvement and a Non-Platform Improvement or the combination thereof without the prior written consent of the other Party. Aytu shall and hereby does assign to Acerus any rights it has or may obtain during the Term in or to any such Platform Improvement, subject to (i) Aytu’s ownership of the NDA and all Know-How contained therein, and (ii) the other rights expressly granted by Acerus to Aytu under this Agreement. Acerus shall and hereby does assign to Aytu any rights it has or may obtain during the Term in or to any such Non-Platform Improvement. Each Party agrees to execute such documents and assignments and take such other actions as reasonably requested by the other Party (and at the requesting Party’s Cost) to effect the assignments and ownership of Intellectual Property Rights as described herein.
Ownership of Developed Technology. Subject to the licenses set forth in this Agreement, all Developed Technology shall be owned solely by PNL.
Ownership of Developed Technology. BioSphere shall own, and be free to use without obligation to DuPont, all Developed Technology. DuPont shall treat all Developed Technology as the Confidential Information of BioSphere in accordance with the obligations of confidentiality set forth in Article 5.
Ownership of Developed Technology. Unless SBTK and Systle agree otherwise, all Developed Technology shall be owned by Systle, subject to the Product Option.
